31
Mar
Mar
One of the most talked-about advances in GLP-based treatments and metabolic research is retatrutide. Although many individuals are familiar with conventional GLP-1 drugs, retatrutide is a new development in metabolic research that acts on several bodily pathways. Retatrutide’s distinct triple-agonist action, which concurrently targets GLP-1, GIP, and glucagon receptors, is attracting more and more attention […]